Major Advanced Solid Tumors Other Than Colorectal
Conditions
Keywords
Pharma Mar, PM01183, Non-Colorectal Cancer (non-CRC), Dose finding phase I
Brief summary
Phase I Study of PM01183 in Non-Colorectal Cancer Patients to determine the recommended dose (RD) of PM01183.
Detailed description
Phase I Study of PM01183 in Non-Colorectal (non-CRC) Cancer Patients to determine the recommended dose (RD) of PM01183, to characterize the safety profile, compliance and feasibility of the schedule, to optimize and individualize PM01183 dosing in non-CRC patients according to individual tolerance, to characterize the pharmacokinetics (PK) of the schedule, to obtain preliminary information on the clinical antitumor activity and to perform an exploratory pharmacogenomics (PGx) analysis.
Interventions
DRUGPM01183
PM01183 drug product (DP) is presented as a lyophilized powder for concentrate for solution for infusion with two strengths, 1 mg and 4 mg vials. Before use, the 1 mg and 4 mg vials should be reconstituted with 2 ml and 8 ml of water for injection respectively, to give a solution containing 0.5 mg/ml PM01183. For administration to patients as an i.v. infusion, reconstituted vials are diluted with glucose 50 mg/ml (5%) solution for infusion or sodium chloride 9 mg/ml (0.9%) solution for infusion.
Sponsors
PharmaMar
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Voluntarily signed and dated written informed consent 2. Age ≥ 18 years. 3. Non or minimally daily activities-interfering disease related symptoms. 4. Life expectancy ≥ 3 months. 5. Patients with solid tumor other than CRC. 6. Adequate bone marrow, renal, hepatic, and metabolic function (tests within normal limits or only minimally altered as assessed ≤ 7 days before inclusion in the study)Recovery to asymptomatic or minimally altered or to baseline from any adverse event (AE) derived from previous treatment (mild alteration for alopecia, skin toxicity or fatigue are allowed). 7. Normal cardiac function cardiac function by appropriate image testing. 8. Women of childbearing potential must have a negative serum pregnancy test before study entry.
Exclusion criteria
1. Primary colorectal cancer diagnosis 2. Prior treatment with PM01183. 3. Concomitant diseases/conditions: a) History of a clinically relevant cardiac condition c) Known chronic liver disease. d) Active uncontrolled infection. e) Known human immunodeficiency virus (HIV) infection. f) Limitation of the patient's ability to comply with the treatment or follow-up protocol. 4. Symptomatic and progressive or corticosteroid-requiring documented brain metastases 5. Men or women of childbearing potential who are not using an effective method of contraception as previously described; women who are pregnant or breast feeding. 6. History of extensive prior pelvic irradiation. 7. History of previous bone marrow and/or stem cell transplantation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recommended dose (RD) | From treatment onset to end of treatment | To determine the recommended dose (RD) of PM01183 administered as a 1-hour infusion intravenously (i.v.) on Days 1 and 8 every three weeks (q3wk) in non-colorectal cancer (non-CRC) patients. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics (PK): The dose-exposure relationships for Cmax and area under the curve (AUC) will be evaluated. | During the infusions administered on Day 1 of Cycles 1 and 3, with a schedule of 13 samples. | To characterize the pharmacokinetics (PK) of this schedule and explore factors that may affect individual variability in main PK parameters. |
| Antitumor activity measured clinically and/or radiologically according to RECIST or by evaluation of tumor markers | Every six weeks while on treatment. Patients who discontinued treatment without disease progression will be followed every three months until disease progression, other antitumor therapy, death or until the end-of-study date, whichever occurs first. | RECIST (Response Evaluation Criteria In Solid Tumors) is a set of published rules that define when cancer patients improve (respond), stay the same (stable) or worsen (progression) during treatments. |
| Pharmacogenomics (PGx) analysis: Number of tumour patient samples with identified and validated putative molecular markers associated with the clinical outcome of non-CRC patients treated with PM01183. | At the end of the study (24 months) | — |
Countries
United States
Outcome results
None listed